At the news
? MIXEDIMPACT 5/10 PRESS-RELEASE filed Mar 27, 2026 at 07:00 ET
Instil Bio reported its Q4 and full-year 2025 financial results, showing a reduced net loss compared to the prior year despite declining cash reserves. The company discontinued development of AXN-2510 and is now focusing on external growth through acquisitions and in-licensing, with a cash runway expected to fund operations beyond 2027.
- Net loss for full year 2025 was $71.37 million ($10.70 per share), improved from $74.14 million ($11.39 per share) in 2024.
- Cash, cash equivalents, restricted cash, and marketable securities declined to $76.3 million as of December 31, 2025, from $115.1 million a year earlier.
- The company discontinued AXN-2510 development and terminated its collaboration with ImmuneOnco Biopharmaceuticals.
- Instil is now pursuing acquisitions and in-licensing opportunities to build a new pipeline.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access